Optimizing use of colistin and polymyxin B in the critically ill

Seminars in Respiratory and Critical Care Medicine

Volumn 28, Issue 6, 2007, Pages 604-614

  Nation, Roger L ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Acinetobacter; Clinical pharmacology; Colistin; Critically ill patients; Polymyxin B; Pseudomonas

Indexed keywords

COLISTIMETHATE; COLISTIN; IMIPENEM; POLYMYXIN B; POLYMYXIN DERIVATIVE; RIFAMPICIN; SULBACTAM; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG STRUCTURE; GRAM NEGATIVE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEUROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; COLISTIN; CRITICAL ILLNESS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B;

EID: 37649021831     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996407     Document Type: Review

References (78)

1. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005;25:11-25
2. Hancock RE. Peptide antibiotics. Lancet 1997;349:418-422
3. Elwood CM, Lucas GD, Muehrcke RC. Acute renal failure associated with sodium colistimethate treatment. Arch Intern Med 1966;118:326-334
4. Brown JM, Dorman DC, Roy LP. Acute renal failure due to overdosage of colistin. Med J Aust 1970;2:923-924
5. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857-868
6. Duncan DA. Colistin toxicity. Neuromuscular and renal manifestations: two cases treated by hemodialysis. Minn Med 1973;56:31-35
7. Bad bugs, no drugs. Infectious Diseases Society of America; 2004. http://www.idsociety.org/badbugsnodrugs.html. Accessed November 16, 2007
8. Livermore DM. The threat from the pink corner. Ann Med 2003;35:226-234
9. Livermore DM. The need for new antibiotics. Clin Microbiol Infect 2004;10(Suppl 4):1-9
10. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheid M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-668
11. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006;12:315-321
12. Sueke H, Marsh H, Dhital A. Using intrathecal colistin for multidrug resistant shunt infection. Br J Neurosurg 2005;19:51-52
13. Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005;31:1058-1065
14. Quinn AL, Parada JP, Belmares J, O'Keefe JP. Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection. Ann Pharmacother 2005;39:949-952
15. Obritsch MD, Fish DN, Maclaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 2005;25:1353-1364
16. Mubareka S, Rubinstein E. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:29-30
17. Michalopoulos A, Kasiakou S, Rosmarakis E, Falagas M. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis 2005;37:142-145
18. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115-121
19. Katragkou A, Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol 2005;43:4916-4917
20. Kasiakou SK, Rafailidis PI, Liaropoulos K, Falagas ME. Cure of post-traumatic recurrent multiresistant gram-negative rod meningitis with intraventricular colistin. J Infect 2005;50:348-352
21. Gump WC, Walsh JW. Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis: case report and review of the literature. J Neurosurg 2005;102:915-917
22. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) gram-negative bacteria. BMC Infect Dis 2005;5:24
23. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005;5:1
24. Bukhary Z, Mahmood W, Al-Khani A, Al-Abdely HM. Treatment of nosocomial meningitis due to a multidrug resistant Acinetobacter baumannii with intraventricular colistin. Saudi Med J 2005;26:656-658
25. Berlana D, Llop JM, Fort E, Badia MB, Jodar R. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005;62:39-47
26. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005;56:128-132
27. Bratu S, Quale J, Cebular S, Heddurshetti R, Landman D. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. Eur J Clin Microbiol Infect Dis 2005;24:196-201
28. Sarria JC, Angulo-Pernett F, Kimbrough RC, McVay CS, Vidal AM. Use of intravenous polymyxin B during continuous venovenous hemodialysis. Eur J Clin Microbiol Infect Dis 2004;23:340-341
29. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-1341
30. Li J, Nation RL, Turnidge JD, et al. Colistin: the reemerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601
31. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:1953-1958
32. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999;33:960-967
33. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006;10:R27
34. Conway SP, Etherington C, Munday J, Goldman MH, Strong JJ, Wootton M. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis. Ann Pharmacother 2000;34:1238-1242
35. Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997;52:987-993
36. Conway SP, Brownlee KG, Denton M, Peckham DG. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med 2003;2:321-332
37. Littlewood JM, Koch C, Lambert PA, et al. A ten year review of Colomycin. Respir Med 2000;94:632-640
38. Ledson MJ, Gallagher MJ, Cowperthwaite C, Convery RP, Walshaw MJ. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 1998;12:592-594
39. Etherington C, Conway SP, Peckham DG, Bosomworth M. Urinary N-acetyl -b-D-glucosaminidase [NAG] in adults with CF: a marker of nephrotoxicity? J Cyst Fibros 2004;3(Suppl 1):549 (abstract 180)
40. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005;39:15-20
41. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-1118
42. Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001;41:645-654
43. Coly-Mycin M. Parenteral [package insert]. Bristol, TN: Monarch Pharmaceuticals; 2005
44. Colomycin injection [summary of product characteristics]. Kent, UK: Forest Laboratories UK Limited; 2004
45. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001;39:183-190
46. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth information supplement (M100-S15). Wayne, PA: Clinical Laboratory Standards Institute; 2005
47. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma studied by high-performance liquid chromatography. Antimicrob Agents Chemother 2003;47:1364-1370
48. Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003;52:987-992
49. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004;53:837-840
50. Li J, Rayner CR, Nation RL, et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005;49:4814-4815
51. Li J, Rayner CR, Nation RL, Owen RJ, Tan KE, Spelman D. Hetero-resistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006;50:2946-2950
52. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 1990;11:319-326
53. Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997;39:255-260
54. Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:3624-3630
55. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007;59:473-477
56. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001;45:781-785
57. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Is once-daily dosing best for colistin against Pseudomonas aeruginosa? In: Proceedings of the Australian Society for Antimicrobials. Melbourne, Australia: 2007
58. Tan CH, Li J, Nation RL. Pharmacodynamics of colistin against Acinetobacter baumannii in an in vitro PD model and development of resistance. In: Proceedings of the Australian Society for Antimicrobials. Sydney, Australia: 2006
59. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic- resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003;47:905-909
60. Zhanel GG, Craig WA. Pharmacokinetic contributions to postantibiotic effects: focus on aminoglycosides. Clin Pharmacokinet 1994;27:377-392
61. Montero A, Ariza J, Corbella X, et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002;46:1946-1952
62. Montero A, Ariza J, Corbella X, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004;54:1085-1091
63. Mahmood I. Allometric issues in drug development. J Pharm Sci 1999;88:1101-1106
64. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006;12:315-321
65. Gilad J, Eskira S, Riesenberg K, Schlaeffer F, Hyam E, Borer A. Emergence of nosocomial colistin-resistant Acinetobacter baumannii. In: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society for Microbiology; 2005
66. Antoniadou A, Kontopidou FV, Poulakou G, et al. Emerging Colimycin resistant strains of Klebsiella pneumoniae from intensive care unit patients. In: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC: American Society for Microbiology; 2005
67. Li J, Nation RL. Old polymyxins are back, is resistance close? Clin Infect Dis 2006;43:663-664
68. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10quiz 1-2
69. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007;44:79-86
70. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001;761:167-175
71. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 2002;46:3304-3307
72. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003;47:1766-1770
73. Coly-Mycin M. Parenteral [package insert]. Mosman, NSW, Australia: Link Medical Products Pty Ltd.; 2006
74. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005;294:813-818
75. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005;41:1159-1166
76. Goodwin NJ, Friedman EA. The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels. Ann Intern Med 1968;68:984-994
77. Jimenez-Mejias ME, Becerril B, Marquez-Rivas FJ, Pichardo C, Cuberos L, Pachon J. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium. Eur J Clin Microbiol Infect Dis 2000;19:970-971
78. Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, Martin-Lozano D, Prados T, Pachon J. Cerebrospinal fluid penetration and pharmacokinetic/ pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002;21:212-214